GlaxoSmithKline is not expected to face generic competition soon for its blockbuster inhaled asthma drug Advair, after Teva Pharmaceutical Industries said gaining FDA approval for a copy would be a major challenge. "The world's top generic company has now admitted that there will be no rapid erosion of Advair by generics, which should assuage the fears of even the most skeptical fund manager," an analyst said.

Full Story:

Related Summaries